PRESS RELEASE published on 11/26/2024 at 17:45, 1 year 11 months ago Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA Valneva submits label extension application to U.S. FDA for its chikungunya vaccine, IXCHIQ®, to potentially include adolescents aged 12 to 17 years and two-year antibody persistence data FDA Valneva Chikungunya Vaccine IXCHIQ Label Extension Application
BRIEF published on 10/10/2024 at 07:05, 2 years ago Valneva presents its outlook at an investor day in New York Investors Growth Valneva Vaccines Lyme
PRESS RELEASE published on 10/10/2024 at 07:00, 2 years ago Valneva Hosts Investor Day in New York City Valneva SE is hosting an investor day in New York City to discuss key value drivers, including Lyme disease vaccine, commercial vaccines, and R&D pipeline. Hybrid event with webcast and Q&A sessions Investor Day Valneva SE Lyme Disease Vaccine R&D Pipeline Commercial Vaccines
BRIEF published on 10/04/2024 at 07:35, 2 years ago Valneva SE Announces Changes in Shares and Voting Rights Euronext Paris Voting Rights Shares Capital Increase Valneva SE
PRESS RELEASE published on 10/04/2024 at 07:30, 2 years ago Valneva SE - Declaration of shares and voting rights - September 30, 2024 Valneva declares changes in shares and voting rights, including a transfer into bearer form and a capital increase without preferential subscription rights Voting Rights Shares Capital Increase Transfer Valneva
BRIEF published on 10/03/2024 at 07:05, 2 years ago Valneva to Hold Investor Day in New York New York Investors Valneva Vaccines Chikungunya
PRESS RELEASE published on 10/03/2024 at 07:00, 2 years ago Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET Valneva SE to host Investor Day at Lotte New York Palace Hotel on Thursday, October 10, 2024, focusing on R&D pipeline and revenue-generating vaccines Investor Day Valneva SE Vaccine R&D Pipeline Lotte New York Palace Hotel
BRIEF published on 09/23/2024 at 15:51, 2 years 1 month ago Valneva Bolstered by Capital Raise Amid Strategic Focus on Vaccine Development BUY Rating Valneva SE Vaccine Development Equity Research Capital Raise
PRESS RELEASE published on 09/23/2024 at 15:46, 2 years 1 month ago Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research updates Valneva SE (FR0004056851) with a BUY rating and a decreased price target to €7.70, reflecting the recent capital raise completed on 13 September 2024 BUY Rating Price Target Valneva SE Equity Research Capital Raise
BRIEF published on 09/23/2024 at 10:59, 2 years 1 month ago Bpifrance crosses the threshold of 10% of VALNEVA voting rights downwards Capital AMF Valneva Threshold Crossing Bpifrance
Published on 10/30/2026 at 23:35, 2 days 10 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 11 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 2 days 15 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 19 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 11/02/2026 at 09:30, 59 minutes ago Europe's first bond for New Space investing is open for subscription from today: European Space Bond, 8% p.a. fixed interest.
Published on 11/02/2026 at 09:20, 1 hour 9 minutes ago Original-Research: SFC Energy AG (von First Berlin Equity Research GmbH): Buy
Published on 11/02/2026 at 09:00, 1 hour 29 minutes ago Original-Research: Gallmetzer HealthCare SpA (von NuWays AG): BUY
Published on 11/02/2026 at 09:00, 1 hour 29 minutes ago Original-Research: bet-at-home.com AG (von NuWays AG): BUY
Published on 11/02/2026 at 09:00, 1 hour 29 minutes ago Mutares has sold SRT Group and its subsidiaries to Quiver
Published on 10/30/2026 at 23:00, 2 days 11 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 16 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 22 hours ago Capital increase through exercise of subscription rights
